Slide 1: Cover letter to stock exchanges
May 28, 2022 Dept. of Corporate Services, Listing Department, BSE Ltd., National Stock Exchange of India Ltd., P J Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Bandra (East), Mumbai – 400 001. Mumbai 400051. BSE Scrip Code : 524735 NSE Symbol : HIKAL Dear Sir/ Madam, Subject: Results
Slide 2: Results Presentation – Q4 FY22
Results Presentation – Q4 FY22
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Hikal Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and
Slide 4: Executive Chairman’s Message
Executive Chairman’s Message “For the financial year ’22, we achieved a PAT of Rs 161 Crores, which is a growth of 21% as compared to last financial year. Our Board of Directors has recommended a final dividend of Rs 0.40 per share (20% of FV). Along with an interim dividend of Rs. 1.20 per share (6
Slide 5: Quarterly Financials Highlights
Quarterly Financials Highlights
Slide 6: Financial Highlights – Q4 FY22
Financial Highlights – Q4 FY22 Revenue – Q4 FY22 EBITDA – Q4 FY22 EBITDA Margin – Q4 FY22 Rs. 502 Crore Rs. 61 Crore 12.2% YoY QoQ YoY QoQ YoY QoQ -6% -2% -44% -34% -837 bps -591 bps PAT – Q4 FY22 EPS – Q4 FY22 Rs. 21 Crore Rs 1.68 YoY QoQ YoY QoQ -59% -54% -59% -54% © Hikal Limited
Slide 7: Quarterly Performance Highlights
Quarterly Performance Highlights Revenue -6% Performance Highlights 532 515 502 • Revenue marginally decreased by 6% on YoY basis to Rs 502 Cr in Q4 FY22 due to • Global slowdown in Generics business due to channel inventory and lower demand/off-take • Production delays due to unavailability of key
Slide 8: Quarterly Performance Highlights – Pharmaceuticals
Quarterly Performance Highlights – Pharmaceuticals Revenue +3% Pharmaceuticals - Performance Highlights 298 308 268 • Revenue remained largely flat at Rs 308 Cr on YoY basis due to lower off-take by customers • EBIT stood at Rs 30 Cr due to • Increase in key raw materials and energy cost due to glob
Slide 9: Quarterly Performance Highlights – Crop Protection
Quarterly Performance Highlights – Crop Protection Revenue -17% Crop Protection - Performance Highlights 235 246 194 • Revenue stood at INR 194 Cr witnessing -17% change on YoY basis due to • Supply chain disruptions in the global market on account of current geo-political situation Q4FY21 Q3FY22 Q4
Slide 10: Quarterly Financial Highlights
Quarterly Financial Highlights Consolidated Revenue Consolidated EBITDA Consolidated PAT 532 109 51 51 515 502 469 96 44 45 457 91 93 61 21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Rs. Crore © Hikal Limited
Slide 11: Quarterly Segmental Highlights
Quarterly Segmental Highlights Pharmaceuticals Revenue Crop Protection Revenue 298 308 274 280 268 246 235 183 190 194 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Pharmaceuticals EBIT Crop Protection EBIT 51 48 48 38 37 36 34 32 30 12 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q4FY
Slide 12: Consolidated Profit & Loss – Q4 FY22
Consolidated Profit & Loss – Q4 FY22 Particulars (Rs. Crore) Q4 FY22 Q4 FY21 Y-o-Y Q3 FY22 Q-o-Q Net Sales 502 532 -6% 514 -2% Expenditure 441 423 420 EBITDA 61 109 -44% 93 -34% Margin 12.2% 20.5% 18.3% Other Income 0 3 -1 Depreciation 24 22 24 Finance Costs 8 8 7 PBT 29 81 -64% 62 -53% Tax 8 30 16
Slide 13: Annual Financial Highlights
Annual Financial Highlights
Slide 14: Financial Highlights - Annual
Financial Highlights - Annual Revenue – FY22 EBITDA – FY22 EBITDA Margin – FY22 Rs. 1,943 Crore Rs. 341 Crore 17.5% FY18-22 FY18-22 YoY YoY YoY CAGR CAGR 13% 5% -124bps 11% 9% PAT – FY22 EPS – FY22 Rs. 161 Crore Rs 13.02 FY18-22 FY18-22 YoY YoY CAGR CAGR 21% 21% 20% 20% © Hikal Limited
Slide 15: Annual Performance Highlights
Annual Performance Highlights Revenue EBITDA PAT +13% +5% +21% 1,943 323 341 161 1,720 133 FY21 FY22 FY21 FY22 FY21 FY22 Pharmaceuticals Division Crop Protection Division +7% +23% 1,060 1,130 813 661 Revenue Revenue FY21 FY22 FY21 FY22 +11% -11% 170 115 151 103 EBIT EBIT Rs. Crore FY21 FY22 FY21 FY2
Slide 16: Yearly Financial Highlights
Yearly Financial Highlights Consolidated Revenue Consolidated EBITDA Consolidated PAT +9% +11% 1,943 341 161 323 1,720 298 +20% 1,590 133 1,507 273 242 1,300 103 84 77 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 Rs. Crore © Hikal Limited
Slide 17: Sales Break-Up
Sales Break-Up Pharmaceuticals Revenue Break-Up Crop Protection Revenue Break-Up CDMO Own products 41.2% 44.5% 54.0% 69.0% 76.7% 75.7% 58.8% 55.5% 46.0% 31.0% 23.3% 24.3% FY20 FY21 FY22 FY20 FY21 FY22 © Hikal Limited
Slide 18: Yearly Segmental Highlights
Yearly Segmental Highlights Pharmaceuticals Revenue Crop Protection Revenue +11% +10% 1,130 813 1,060 939 887 651 661 620 753 547 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 Pharmaceuticals EBIT Crop Protection EBIT +7% +11% 170 112 115 151 100 103 129 128 87 99 FY18 FY19 FY20 FY21 FY22 FY18 F
Slide 19: Consolidated Profit & Loss – Full Year
Consolidated Profit & Loss – Full Year Particulars (Rs. Crore) FY22 FY21 Y-o-Y Net Sales 1,943 1,720 13% Expenditure 1,602 1,397 EBITDA 341 323 3% Margin 17.5% 18.8% Other Income 5 5 Depreciation 96 85 Finance Costs 31 36 Exceptional Item - - PBT 219 206 6% Tax 58 73 Net Profit 161 133 21% Margin 8.
Slide 20: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (Rs. Crore) Mar-22 Mar-21 Equities & Liabilities (Rs. Crore) Mar-22 Mar-21 Total Non Current Assets 1,249 1,035 Shareholders Fund 1,068 933 Property, Plant and Equipment 815 646 Share Capital 25 25 Capital work in Progress 285 245 Other Equity 1,043 909 Right to Use
Slide 21: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. Crore) Full Year ended 31-Mar-22 Full Year ended 31-Mar-21 Profit before tax 219 206 Adjustments 128 127 Operating Profit Before Working Capital Changes 345 333 Change in operating assets and liabilities 19 (58) Cash generated from operations 364 276
Slide 22: Ratio Analysis
Ratio Analysis ROE ROCE 16.1% 15.2% 15.0% 16.2% 12.8% 15.2% 12.5% 14.5% 12.0% 10.7% FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 Net Debt / Equity Net Debt / EBITDA 0.91 2.51 0.83 2.11 2.13 0.71 0.61 1.78 1.81 0.59 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 © Hikal Limited
Slide 23: Annual Dividend Payout
Annual Dividend Payout Dividend Payout 14% 24% 22% 18% 19% 17% 20% 19% 19% 12% including DDT 13.02 EPS DPS 10.80 8.36 6.85 6.27 5.70 5.18 3.28 3.35 2.05 2.00 1.20 1.60 1.00 1.00 1.20 1.20 1.20 0.90 0.50 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 The above dividend is based on Face Value of Rs
Slide 24: Contact Us
Contact Us Company : Investor Relations Advisors : Hikal Limited Strategic Growth Advisors Pvt. Ltd. CIN: L24200MH1988PTC048028 CIN: U74140MH2010PTC204285 Mr. Kuldeep Jain Mr. Jigar Kavaiya / Mr. Aakash Mehta +91-9920602034 / +91-9819178243 Kuldeep_jain@hikal.com jigar.kavaiya@sgapl.net / aakash.meh
Slide 25: HIKAL
HIKAL